DRW Securities’s VistaGen Therapeutics VTGN Stock Holding History

DRW Securities’s Portfolio VTGN Stock Details VTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-10,000	Closed	-$6.62K	–	1760
2025 Q4	$6.62K	Buy	+10,000	New	+$36.1K	﹤0.01%	1186

Other funds holding VTGN

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

DRW Securities's VTGN Position: Q1 2026 in Review

DRW Securities sold out of VistaGen Therapeutics (VTGN) in Q1 2026, closing a stake of 10,000 shares — an estimated $6.62K sold.

DRW Securities first reported a position in VTGN in Q4 2025 and held it in 1 quarter. The position peaked at $6.62K in Q4 2025. 56 funds tracked by Wall St. Rank hold VTGN as of Q1 2026.

DRW Securities reported no remaining VistaGen Therapeutics position as of Q1 2026 after selling out during the quarter.
DRW Securities sold 10,000 VistaGen Therapeutics shares in Q1 2026, an estimated $6.62K.
DRW Securities first reported a position in VistaGen Therapeutics in Q4 2025 and held it in 1 quarter.
DRW Securities's VistaGen Therapeutics position peaked at $6.62K in Q4 2025.
56 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2026.

Based on DRW Securities's 13F filing for Q1 2026, filed 13 May 2026.